Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration

Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.

Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

Asia Pacific Infectious Disease Therapeutics Market Overview

The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.

Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Infectious Disease Therapeutics Market Segmentation

The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific infectious disease therapeutics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific infectious disease therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.